EyePoint (EYPT) shares soared 15.2% in the last trading session to close at $14.91. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 14.2% loss over the past four weeks.EyePoint Pharmaceuticals’ pricesurge is likely tied to the company’s positive developments surrounding its lead candidate, Duravyu. Investor enthusiasm was driven by encouraging clinical progress, particularly around late-stage trial safety and advancement mileston ...

– Seasoned commercial executive with over 30 years of leadership in retinal disease across biotech and large pharma –– Brings established track record of successful product launches and oversight of prominent ophthalmology franchises, including Lucentis® and Xiidra® – WATERTOWN, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced th ...

Core Insights - Wall Street analysts are showing strong confidence in four clinical-stage biotech companies, with potential price targets indicating gains of up to 384% [1] - These companies are characterized by significant risks but have compelling late-stage pipelines and upcoming catalysts that attract institutional investors [1] Company Summaries EyePoint Pharmaceuticals - Current trading price is $12.94 with a consensus target of $36.08, suggesting a 179% upside [2] - The lead candidate, Duravyu, targets diabetic macular edema and wet age-related macular degeneration, with pivotal Phase 3 trials starting in Q1 2026 [2] - Q3 2025 revenue was $5.33 million, down from $10.52 million a year prior, with a net loss of $59.4 million and cash reserves of $71.1 million [3] - All 13 analysts rate it Buy or Strong Buy, with the stock having doubled over the past year but down 29% year-to-date [3] Janux Therapeutics - Trading at $13.14 with a consensus target of $63.59, indicating a 384% potential upside [4] - The company’s TRACTr and TRACIr platforms are designed for tumor-activated T-cell engagement, with two candidates in clinical trials [4] - Q3 2025 revenue surged to $10.0 million from $439,000 a year earlier, with a net loss of $24.31 million and R&D expenses nearly doubling to $34.63 million [5] - Cash position stands at $989 million, with all 19 analysts rating it Buy or Strong Buy [5] Kyverna Therapeutics - Currently trading at $7.26, with analysts targeting $29.60, implying a 308% upside [6] - The lead candidate, KYV-101, is in late-stage trials for stiff person syndrome and myasthenia gravis, with positive interim data supporting its clinical thesis [6][7] - Q3 2025 net loss was $36.8 million, better than estimates, and the company has secured a $150 million loan facility alongside $171.1 million in cash [7] - All six analysts rate it Buy or Strong Buy, with the stock having surged 139% over the past year [7] Viking Therapeutics - Trading at $29 with a consensus target of $92.72, representing a 220% upside [8] - The lead drug, VK2735, is a dual GLP-1/GIP agonist in Phase 3 trials, with significant patient enrollment [8] - Q4 2025 net loss was $157.7 million, missing estimates, while R&D expenses increased significantly [9] - Cash reserves are at $706 million, with 17 out of 18 analysts rating it Buy or Strong Buy [9] Industry Overview - The four companies represent high-conviction investments in clinical-stage biotech, with Viking's obesity market positioning offering the largest potential opportunity [10] - Kyverna's CAR T approach addresses unmet needs in autoimmune diseases, while Janux's platform technology provides multiple avenues for success [10] - EyePoint's more mature pipeline includes near-term catalysts, and all four companies carry inherent clinical-stage risks but have strong analyst support indicating favorable risk-reward profiles for patient investors [10]

EyePoint Pharmaceuticals Conference Call Summary Company Overview - **Company**: EyePoint Pharmaceuticals (NasdaqGM:EYPT) - **Event**: 2026 Conference at Guggenheim Emerging Biotech Summit - **Key Speaker**: George Elston, Chief Financial Officer Core Industry Insights - **Industry**: Biotechnology, specifically focusing on ophthalmology and retinal diseases - **Key Products**: DURAVYU, a small molecule tyrosine kinase inhibitor (vorolanib) using Durasert E technology Key Points and Arguments Clinical Trials and Data - **Wet AMD Trials**: - Two Phase 3 trials fully enrolled with over 900 patients combined, each trial enrolling over 450 patients in about 7 months, a record time for wet AMD [2][3] - First trial, LUGANO, expected to read out mid-year 2026, followed by LUCIA a few months later [6][8] - Non-inferiority trial against aflibercept with a margin of -4.5 letters [18][32] - Safety profile remains strong with no significant adverse events reported in 190 patients across four trials [21][72] - **DME Trials**: - Two Phase 3 trials (COMO and CAPRI) initiated, each with 240 patients, with first patient dosing expected this quarter [104][106] - DME market estimated at $3 billion in the U.S., dominated by anti-VEGF treatments [107] Product and Technology - **DURAVYU**: - Designed for at least six-month dosing, utilizing a fully bio-erodible insert [10] - Aims to provide a new mechanism of action in wet AMD treatment, allowing for potential combination with existing therapies [12][22] - Expected to reduce treatment burden significantly, with previous trials showing an 80%+ reduction in treatment burden [40] Market Potential and Strategy - **Market Size**: - Wet AMD market valued at $12 billion, with 25%-40% of patients potentially suitable for DURAVYU [93] - Comparison made to VABYSMO, which achieved $4 billion in sales within two and a half years [93] - **Commercial Strategy**: - Plans to launch DURAVYU independently with a commercial team of about 70 representatives [96] - Established relationships in the retina community to facilitate market entry [96] Financial Health - **Cash Position**: - Ended 2025 with $300 million in cash, sufficient to fund ongoing pivotal programs and NDA submissions through Q4 2027 [110] Additional Important Insights - **Safety Monitoring**: - Data Monitoring Committee (DMC) has recommended no changes to the trial protocols, indicating confidence in safety [70] - **Regulatory Pathway**: - NDA submission planned with one-year safety and efficacy data, followed by a supplemental NDA for two-year data [92] - **Patient Population**: - Phase 3 trials include 75% newly diagnosed patients, which is expected to improve outcomes compared to the Phase 2 trial population [57][60] - **Manufacturing Capability**: - Northbridge, Massachusetts manufacturing facility operational, ensuring readiness for FDA expectations [8] This summary encapsulates the key points discussed during the conference call, highlighting EyePoint Pharmaceuticals' strategic direction, clinical trial progress, market potential, and financial health.

Company Overview - EyePoint, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for serious retinal diseases [3][4] - The company's lead product candidate, DURAVYU™, is an investigational sustained delivery treatment combining vorolanib, a selective tyrosine kinase inhibitor, with next-generation bioerodible Durasert E™ technology [3][5] - EyePoint has a history of four approved drugs over three decades and has treated tens of thousands of eyes with its innovations [4] Product Development - DURAVYU™ is currently undergoing Phase 3 pivotal trials for wet age-related macular degeneration, with topline data expected in mid-2026 [3] - The first patient dosing in the pivotal Phase 3 clinical trials for diabetic macular edema is anticipated in the first quarter of 2026 [3] Corporate Events - George O. Elston, Executive Vice President and Chief Financial Officer of EyePoint, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026 [1] - A webcast and archived replay of the fireside chat will be available on the company's website [2]

Company Overview - EyePoint is a leader in sustained-release drug delivery for retinal diseases [3] - The company's lead product, DURAVYU, is currently in Phase III trials for wet age-related macular degeneration [3] - Both Phase III trials for DURAVYU are fully enrolled, with top-line data expected midyear [3] Product Development - DURAVYU is also in Phase III trials for diabetic macular edema (DME), with the first patients expected to be dosed this quarter [3] - The proprietary delivery system, Durasert, has been utilized in four FDA-approved products, demonstrating a strong safety and efficacy record [3] Leadership and Experience - EyePoint has a veteran leadership team with over three decades of experience in clinical drug development and successful commercialization [3]

EyePoint Pharmaceuticals Conference Call Summary Company Overview - **Company**: EyePoint Pharmaceuticals (NasdaqGM:EYPT) - **Industry**: Biotechnology, specifically focused on sustained-release drug delivery for retinal diseases Key Points and Arguments Product Development - **Lead Product**: Duraview, currently in phase III trials for wet age-related macular degeneration (AMD) and diabetic macular edema (DME) [2][4] - **Trial Status**: Both phase III trials for wet AMD are fully enrolled, with top-line data expected mid-year 2026 [2][12] - **Durasert Technology**: Proprietary delivery system with a strong safety and efficacy record, used in four FDA-approved products [3][6] - **Financial Position**: Approximately $300 million in cash, providing a runway well past data readouts into the end of 2027 [4][55] Market Potential - **Market Size**: The retinal disease market is significant, with recent products like Vabysmo generating nearly $4.5 billion in revenue [4][31] - **Unmet Needs**: Key unmet needs in VEGF-mediated diseases include longevity of treatment and new mechanisms of action [5][6] - **Competitive Landscape**: EyePoint aims to be first to market with a sustained-release option, competing against established products like Eylea and Vabysmo [12][44] Clinical Trial Insights - **Efficacy**: Duraview showed statistically non-inferior results compared to Eylea in previous trials, with a significant reduction in treatment burden (75%-90%) [17][41] - **Safety Profile**: No reported ocular systemic serious adverse events (SAEs) in completed trials, with ongoing monitoring showing similar safety [11][12] - **DME Trials**: Two phase III trials (COMO and CAPRI) are underway, leveraging safety data from wet AMD trials [24][52] Product Advantages - **Multi-Mechanism of Action (MOA)**: Duraview blocks both VEGF and IL-6, addressing inflammation and vascular leakage [5][6][9] - **Durability**: Sustained release for at least six months, with potential for longer intervals between doses [10][18] - **Convenience**: Can be stored at room temperature, unlike competitors that require refrigeration [9] Commercial Strategy - **Market Adoption**: Education of physicians on the dual mechanism of action and integration into existing treatment regimens is crucial for adoption [49] - **Regulatory Pathway**: Trials designed in alignment with FDA and EMA, aiming for a non-inferiority regulatory pathway [13][14] Future Outlook - **Data Readouts**: Top-line data for wet AMD trials expected in mid-2026, with DME trials following [14][29] - **Cash Management**: Sufficient cash reserves to support ongoing trials and commercial buildout [55][56] Additional Important Information - **Facility**: EyePoint has a commercial manufacturing facility in Northbridge, Massachusetts, built to FDA and EMA standards, capable of producing hundreds of thousands of inserts annually [22][56] - **Physician Feedback**: Positive feedback from physicians regarding Duraview's unique profile and potential to reduce treatment burden [32][47] - **Competitive Trials**: Ongoing studies in the TKI space are expected to show positive results, reinforcing the efficacy of TKIs in retinal diseases [50] This summary encapsulates the critical insights from the conference call, highlighting EyePoint Pharmaceuticals' strategic positioning, product development, and market potential in the retinal disease sector.

J.P. Morgan Healthcare Conference Presentation January 13, 2026 Jay S. Duker, M.D. President and CEO © 2026 EyePoint. All Rights Reserved. Legal Disclaimers Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in t ...

Investor Presentation January 2026 © 2026 EyePoint. All Rights Reserved. Legal Disclaimers Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the future, are forward-looking statements, including but not limit ...

Product Development - EyePoint's lead product candidate, DURAVYU™, is currently in Phase 3 trials for wet AMD and DME, with topline data expected in mid-2026[2] - Over 900 patients have been enrolled in the Phase 3 LUGANO and LUCIA trials within 7 months, making it one of the fastest enrolling wet AMD pivotal programs[4] - The Phase 3 wet AMD program has a primary endpoint of noninferiority in best corrected visual acuity (BCVA) at weeks 52 and 56, compared to aflibercept[6] - First patient dosing in the Phase 3 DME trials (COMO and CAPRI) is expected in Q1 2026, with each trial enrolling approximately 240 patients[6] - The independent Data Safety Monitoring Committee recommended the continuation of the Phase 3 program with no protocol modifications[6] Treatment Efficacy - DURAVYU demonstrated an 88% reduction in treatment burden six months after treatment, with over 80% of patients being supplement-free or requiring only one supplemental anti-VEGF injection[10] - DURAVYU's multi-mechanism of action includes a greater than 50% reduction in IL-6 activity, which is significant for treating wet AMD and DME[6] - DURAVYU is positioned as the only sustained release TKI in development for DME, addressing a significant need for new therapeutic options[3] Financial Overview - The company completed a public offering with gross proceeds of $172.5 million in October 2025, with approximately $300 million in cash and investments as of December 31, 2025[6] - EyePoint is preparing for an expeditious NDA filing and FDA review to deliver DURAVYU to patients as soon as possible[3]